Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Debt to Equity (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Debt to Equity for 4 consecutive years, with $3.44 as the latest value for Q3 2025.

  • On a quarterly basis, Debt to Equity changed N/A to $3.44 in Q3 2025 year-over-year; TTM through Sep 2025 was $3.44, a N/A change, with the full-year FY2021 number at $0.05, down 35.04% from a year prior.
  • Debt to Equity was $3.44 for Q3 2025 at Vivos Therapeutics, up from $1.73 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $3.44 in Q3 2025 to a low of $0.03 in Q2 2021.